{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"pt-141-glp-1","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-glp-1/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/pt-141-glp-1/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-glp-1/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-glp-1/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-glp-1/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-glp-1/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/pt-141-glp-1/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"pt-141-glp-1","title":"PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:06.022Z","body_excerpt":"## What's breaking down\n\nNo single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.\n\n## Why PT-141 might help you\n\nPT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This can reduce overall body weight, which in turn lowers mechanical stress on joints and the spine in weight-sensitive individuals. At the same time, rapid weight loss carries tradeoffs such as potential muscle loss or gut slowing. The class therefore primarily supports metabolic repair pathways while suppressing hunger signals. Whether this helps or trades off against other layers depends on the individual balance between sustained weight reduction and any reported shifts in energy or desire.\n\n## How these fit together\n\nSingle-compound focus applies here. PT-141 targets the sexual / CNS arousal layer through MC4R agonism. GLP-1 agonists target metabolic layers. The two do not overlap in primary mechanism, so any combined use would map to separate degeneration layers without repetition: metabolic support from the agonist plus central arousal support from PT-141 if needed. Recent human data on co-administration for obesity showed additive effects on weight loss without added safety signals in the tested regimen.\n\n## What the evidence actually shows\n\nHuman data exist for both compounds separately and in limited combination. Two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant gains in sexual desire scores and reductions in distress versus placebo over 24 weeks (human tier). Nausea, flushing, and headache occurred more frequently with the drug. A phase 2 randomized double-blind placebo-controlled trial (BMT-801) of bremelanotide co-administered with tirzepatide met its primary endpoint for weight loss, showed additive and synergistic weight reduction at low doses, and indicated the melanocortin agonist halted rapid weight regain after tirzepatide cessation; co-administration did not increase tolerability or safety issues (human tier, 2025).\n\nGLP-1 agonist effects on sexual function show mixed human signals. Case reports document anorgasmia onset shortly after starting liraglutide or semaglutide that resolved after switching to tirzepatide. FAERS database analysis identified 182 reports of male sexual dysfunction (orgasmic dysfunction, erectile dysfunction, decreased libido) with various GLP-1 agonists, though disproportionality measures indicated only a weak association. Some observational and survey data note both increased and decreased desire after GLP-1 initiation, often linked to weight change or side effects. No large dedicated human trials examine PT-141 specifically for GLP-1-related sexual changes.\n\nPreclinical data are limited in the returned results. Animal models originally supported melanocortin effect","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placebo (human).","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes human efficacy tier for PT-141 on the arousal layer.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented post-tirzepatide regain without added safety signals (human, 2025).","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s9"],"source_status":"sourced","why_material":"Direct human evidence on the PT-141 + GLP-1 combination.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human).","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s14"],"source_status":"sourced","why_material":"Illustrates possible sexual-function layer interaction.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c4","text":"FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human).","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s30"],"source_status":"sourced","why_material":"Quantifies signal strength in real-world reporting.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c5","text":"Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal).","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s33"],"source_status":"sourced","why_material":"Captures community experience tier.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Phase 3 RECONNECT trials results.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"55e0355b8877a219394bd379bc839885db127281572b42e11078d52e0026d119"},{"id":"s9","type":"news","url":"https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/","title":"Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study","quote":"The data demonstrated that co-administration was additive and synergistic, resulting in increased weight loss, and that co-administration did not result in increased tolerability or safety issues for patients.","summary":"Phase 2 combination trial topline.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"76bfcde06e1c2bf471824fc6d99839215380d49b28e9884222c1545715bc54ab"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12260840/","title":"Anorgasmia following initiation of GLP-1 agonist","quote":"Within 2 weeks of initiating the medication, she noticed a change in her sexual function, specifically anorgasmia.","summary":"Case of GLP-1 linked anorgasmia.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"ae9f8a74f6b453642f85c43b3a5f64cf84c84cf0f7a6f02262e205ae93dd2d16"},{"id":"s30","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40240532/","title":"Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data","quote":"low ROR (0.41... ) suggest a weak association.","summary":"FAERS disproportionality analysis.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"a0c79fa14d9555ba1ff03d07c3496e9dc4c51e146d884086d01e98fbf4916139"},{"id":"s33","type":"reddit","url":"https://www.reddit.com/r/glp1/comments/1i6khhz/are_glp1_medications_affecting_your_libido_a/","title":"Are GLP-1 Medications Affecting Your Libido?","quote":"They all lowered my craving for sex. By a lot.","summary":"User reports of libido change on GLP-1.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"cc533e66f90b30723c397a690f60d7977994ba494bb684933c8f1d6f1b815668"}],"anecdotal_sources":[{"id":"s33","type":"reddit","url":"https://www.reddit.com/r/glp1/comments/1i6khhz/are_glp1_medications_affecting_your_libido_a/","title":"Are GLP-1 Medications Affecting Your Libido?","quote":"They all lowered my craving for sex. By a lot.","summary":"User reports of libido change on GLP-1.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"cc533e66f90b30723c397a690f60d7977994ba494bb684933c8f1d6f1b815668"}],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Phase 3 RECONNECT trials results.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"55e0355b8877a219394bd379bc839885db127281572b42e11078d52e0026d119"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12260840/","title":"Anorgasmia following initiation of GLP-1 agonist","quote":"Within 2 weeks of initiating the medication, she noticed a change in her sexual function, specifically anorgasmia.","summary":"Case of GLP-1 linked anorgasmia.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"ae9f8a74f6b453642f85c43b3a5f64cf84c84cf0f7a6f02262e205ae93dd2d16"},{"id":"s30","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40240532/","title":"Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data","quote":"low ROR (0.41... ) suggest a weak association.","summary":"FAERS disproportionality analysis.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"a0c79fa14d9555ba1ff03d07c3496e9dc4c51e146d884086d01e98fbf4916139"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"pt-141-glp-1","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":5,"anecdotal":1,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}